How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.
Exclusive Interviews
We put the questions to top biotech and pharma CEOs, discussing science, economics and leadership. If you have questions you want answered, don't forget to leave them in the comment section.
71 stories
Make us preferred on GoogleLatest stories
Page 5 of 5
This new blood test could change everything for immunocompromised patients
Alec Ford explains how the Karius Test® uses cutting-edge genomics to detect infections caused by more than 1,000 pathogens within a day of receiving a blood sample, offering a breakthrough for immunocompromised patients, particularly those with cancer.
What a 10 year mission to become a leading CRO looks like
Julie Ross took the helm of Advanced Clinical over a decade ago. Now, they are one of the largest private CROs in America, and have helped biotechs and pharma in 54 countries take their life-saving drugs from concept to clinic.
This startup could save big pharma millions of dollars using a new AI translatability platform
AI and drug discovery are multi-billion dollar markets, but money (and data) is wasted every year from a poor understanding and implementation of translatability from animal models to humans. Dr. Jo Varshney's BIOiSIM platform seeks to change that.
How big could the GLP-1 activator market be?
There is a huge boom in the newfound 'GLP-1 supplements' industry, and New Zealander CaloCurb is taking advantage, seeing 400% to 600% growth per quarter. They are now in the middle of their fourth, and largest, human trial - but will strong clinical results be enough to capture the market?
Opentrons, backed by SoftBank & Khosla, is bringing lab automation to the masses
It took little over 40 Opentrons robots to provide the majority of COVID-19 testing for the city of New York - 15 million people. Top-tier investors have piled in, will their bets pay off in 2025?
New CEO Dr. Mike Exton has big plans for Lexicon Pharma in 2025
Lexicon has been discovering new genetic science since the Human Genome Project. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this summer and has plans to make history.
